Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTKA5LP)

DTT Name	HGF/Met signaling pathway (HGF/Met pathway) DTT Info
Gene Name	HGF/Met pathway

Molecule-Related Drug & Molecule List

Molecule-Related Drug List

Molecule Type:

DTT

DTP

DME

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

1 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[1]
------------------------------------------------------------------------------------

1 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fosgonimeton	DMXMAJA	Alzheimer disease	8A20	Phase 2/3	[2]
------------------------------------------------------------------------------------

1 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SAIT301	DMLU6J0	Nasopharyngeal carcinoma	2B6B	Investigative	[3]
------------------------------------------------------------------------------------

Molecule Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

References

1	Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.Drug Des Devel Ther. 2015 Aug 26;9:4897-907.
2	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial. J Alzheimers Dis. 2022;86(3):1399-1413.
3	Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.